The European Medicines Agency’s advisory group CHMP has adopted a positive opinion recommending approval of Pfizer’s (NYSE:PFE) Nyvepria (pegfilgrastim), a biosimilar to Amgen’s (NASDAQ:AMGN) Neulasta.
A final decision from the European Commission usually takes ~60 days.
https://seekingalpha.com/news/3615272-european-advisory-group-back-pfizers-neulasta-biosimilar
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.